Dedicated to discovering new cannabis cultivars for disease-specific actions INVESTOR PRESENTATION March 2016
1 Dedicated to discovering new cannabis cultivars for disease-specific actions Content 3 Veritas Pharma 4 The Veritas-Cannervert Alliance 5 The Veritas-Whistler Alliance 6 Veritas’ Research Aims 6 Veritas Research Advantages 7 Veritas’ Targeted Medical Conditions 9 Medicinal Marijuana Market in Colorado & Oregon 9 The Research 10 Toxicological & Therapeutic Effect Profiling 11 Intellectual Property Strategy 12 Veritas Research Timetable* 13 Market Strengths and Weaknesses 13 Cannabis Related Drugs 14 Current Cannabinoid Drugs in Development 15 Veritas Investment & Financing 16 Use of Proceeds 17 Veritas Pharma Team 18 Anticipated Milestones & Potential News Flow 19 Veritas Pharma Share Structure pre- and post- financing INVESTOR PRESENTATION • March 2016
2 Dedicated to discovering new cannabis cultivars for disease-specific actions Legal Disclaimer Forward Looking Information This document provides a description of Veritas This corporate document contains statements Pharma Inc. (“Company” or the “Company”) and that, to the extent that they are not historical fact, its business. Prospective investors are encouraged may constitute “forward-looking statements” to obtain independent legal advice concerning within the meaning of applicable securities any investment in securities of Company and legislation. Any statements regarding future should not base their decision on whether to invest plans, objectives or economic performance of in Company solely upon the material provided Company , or the assumption underlying any herein. There are no representations or warranties of the foregoing, constitute forward-looking made herein by Company or the agents, if any, information. This corporate document may use of the proposed offering of any securities or debt words such as “may”, “would”, “could”, “will”, instruments in the Company (the “Agents”) “likely”, “except”, “anticipate”, “believe”, “intend”, and investors will only be able to rely on the “plan”, “forecast”, “project”, “estimate”, “outlook”, representations and warranties contained in the and other similar expressions to identify forward- subscription agreement to be entered into at the looking statements. Actual results, performance time of sale of the securities. There are certain or achievement could differ materially from that risks inherent in an investment in the securities expressed in, or implied by, any forward-looking of Company that prospective investors should statements in this corporate document, and, carefully consider before investing in the securities accordingly, investors should not place undue of the Company. This document constitutes an reliance on any such forward-looking statements. offering of the securities described herein only in Forward-looking information involves significant those jurisdictions and to those persons where and risks, assumptions, uncertainties and other factors to whom they may be lawfully offered for sale, and that may cause actual future results or anticipated only by persons permitted to sell these securities. events to differ materially from those expressed This document is not, and under no circumstances or implied in any forward-looking statements and is it to be construed as an advertisement or a accordingly, should not be read as guarantees of public offering of these securities. This document is future performance or results. Any forward-looking personal to each offeree and does not constitute an statements speak only as of the date on which offer to any other person or to the public generally such statement is made and each of Company and to subscribe for or otherwise acquire the Agents disclaims any intention or obligation to any of the securities referred to herein. update or revise any forward-looking information, No securities regulatory authority or similar whether as a result of new information, future authority has reviewed or in any way passed events or otherwise, unless required by applicable upon the presentation or the merits of these law. New factors emerge from time to time, and securities and any representation to the contrary it is not possible for management to predict all of is an offence. This document has been prepared such factors and to assess in advance the impact for information purposes only in order to assist of each such factors. prospective investors in evaluating an investment in Company . No representation, warranty or undertaking, express or implied, is made and no responsibility or liability is accepted by the Agents as to the accuracy or completeness of the information contained herein or any other information, representation, warranty or undertaking, express or implied, made by Company in connection with the offering of securities described herein. INVESTOR PRESENTATION • March 2016
• An alliance of: • Located in Vancouver, Canada on (currently cross listing on OTC: VRTHF and Frankfurt: 2VP) 3 Dedicated to discovering new cannabis cultivars for disease-specific actions Veritas Pharma... • A discovery & development company dedicated to finding new cannabis cultivars for disease-specific actions – Academic pharmacologists, anesthetists, chemists – Pharmaceutical industry specialists – Major medicinal marijuana producer – Professional financiers The University of British Columbia campus • Canadian Securities Exchange (CSE) listed company; symbol ‘VRT’ INVESTOR PRESENTATION • March 2016
papers and authorship of 20 patents. A UBC Emeritus Professor and an anesthesiologist legal aspects of drug use. He has >70 scientific He presently consults on medicinal chemistry and He holds patents on analgesics and EEG techniques and biochemistry. His experience is in developing His research focuses on chronic pain management, • Dec. 18, 2015, Veritas entered into a Share Purchase Agreement to acquire Cannevert Therapeutics Ltd., dedicated to cannabis cultivar research aimed at specific clinical utility • Agreement: – Veritas will invest $1.5m over 18 at Vancouver Hospital. He co-founded several months ($250K per quarter) – Veritas will own 80% of Cannevert when payment complete and Verona Pharma plc (AIM: VRP). – Remaining 20% of Cannevert acquired with Veritas shares (after an independent He holds numerous patents and has founded several An Emeritus Professor at University of British 4 Dedicated to discovering new cannabis cultivars for disease-specific actions The Veritas-Cannevert Alliance valuation of Cannevert) Cannevert Therapeutics Scientists PROF. MICHAEL J. A. WALKER, PROF. ERNEST PUIL, PhD President & Head of Biology PhD Pharmacology Consultant An active Emeritus Professor at UBC and Columbia (UBC) and an international expert on an international expert in CNS pharmacology. general pharmacology, toxins, pharmacology of He is the current CEO of Therexcell Pharma Inc. excitable tissues, and drug design and development. for predicting effects of medication in anesthesia public and private biotechs in Canada and the UK, and epilepsy. including Cardiome Pharma Corp. (TSX: COM), DR. THOMAS STOKES, PhD Chemistry Consultant DR. BERNARD A. MACLEOD, An ethnopharmacologist and currently the chief MD Senior Clinical Scientist medicinal chemist at Therexcell Pharma Inc. He is also a consultant for Biofine International Inc., a company which specializes in the custom synthesis companies including Cardiome Pharma Corp. of chemicals for the pharmaceutical industry. He brings 30 years of experience as a specialist in preclinical pharmacology and clinical research. DR. ANDREW HEGLE, PhD Senior Scientist PROF. RICHARD A. WALL, A UBC Adjunct Professor with expertise PhD Principal Chemist in experimental physiology, pharmacology A UBC Emeritus Professor with expertise is in the chemical aspects of drug effects on the body. industrial analytical chemistry systems and he helped to establish the first cannabinoid research laboratory at UBC. DR. RICARDO RIVERA-ACEVEDO, PhD Senior Scientist A UBC Adjunct Professor with expertise in experimental pharmacology and pathophysiology, which led him to establish the first analytical laboratory for cannabinoid research at UBC. INVESTOR PRESENTATION • March 2016
• Veritas has entered into a strategic alliance with Whistler Medical Marijuana Corp.: – Whistler representatives will sit on the Veritas Advisory Board – Whistler will be the source of marijuana cultivars for Cannevert over the next 18 months – Veritas & Cannevert will conduct analytical, pharmacological and clinical testing of these 5 Dedicated to discovering new cannabis cultivars for disease-specific actions The Veritas – Whistler Alliance – Whistler is licensed by Health Canada to produce dried or fresh marijuana as well as cannabis oil cultivars to assess their therapeutic potential • Jesse McConnell, Whistler co-founder & principal contact at jessemcconnell1@icloud.com ; Website: www.whistlermedicalmarijuana.com INVESTOR PRESENTATION • March 2016
Recommend
More recommend
